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ABSTRACT
Glioblastomas (GBMs), the most aggressive primary brain tumors, exhibit 
increased invasiveness and resistance to anti-tumor treatments. We explored the 
role of RTVP-1, a glioma-associated protein that promotes glioma cell migration, 
in the mesenchymal transformation of GBM. Analysis of The Cancer Genome Atlas 
(TCGA) demonstrated that RTVP-1 expression was higher in mesenchymal GBM and 
predicted tumor recurrence and poor clinical outcome. ChiP analysis revealed that 
the RTVP-1 promoter binds STAT3 and C/EBPβ, two master transcription factors 
that regulate mesenchymal transformation of GBM. In addition, IL-6 induced RTVP-1 
expression in a STAT3-dependent manner. RTVP-1 increased the migration and 
mesenchymal transformation of glioma cells. Similarly, overexpression of RTVP-1 
in human neural stem cells induced mesenchymal differentiation, whereas silencing 
of RTVP-1 in glioma stem cells (GSCs) decreased the mesenchymal transformation 
and stemness of these cells. Silencing of RTVP-1 also increased the survival of 
mice bearing GSC-derived xenografts. Using gene array analysis of RTVP-1 silenced 
glioma cells we identified IL-6 as a mediator of RTVP-1 effects on the mesenchymal 
transformation and migration of GSCs, therefore acting in a positive feedback loop by 
upregulating RTVP-1 expression via the STAT3 pathway. Collectively, these results 
implicate RTVP-1 as a novel prognostic marker and therapeutic target in GBM.
INTRODUCTION
Glioblastoma (GBM) are the most common and 
aggressive astrocytic tumors and are characterized by 
increased proliferation, invasion into the surrounding 
normal tissue, robust angiogenesis and resistance to 
conventional therapies [1]. The prognosis of patients 
with GBM remains extremely poor and has not 
changed significantly during the past several years 
[2, 3]. GBM contain a small subpopulation of cancer 
stem cells (i.e., glioma stem cells [GSCs]) [4, 5] that 
are characterized by self-renewal ability, multi-lineage 
differentiation potential and the ability to generate tumors 
that recapitulate the parental tumors [6]. In recent years, 
GSCs have been implicated in treatment resistance and 
tumor recurrence of GBM [7].
Recently, gene expression profiling studies have 
identified four GBM subtypes that were classified based 
on their transcriptional signatures into proneural, neural, 
classical and mesenchymal subtypes [8–12]. These 
subtypes have distinct differential genetic alterations, 
molecular signature, cellular phenotypes and patient 
prognosis. [9, 13–15].
Recent studies identified the transcription factors 
(TFs), signal transducer and activator of transcription 3 
(STAT3) and CCAAT enhancer-binding protein β 
(C/EBPβ) as synergistic initiators and master regulators 
of the mesenchymal transformation in GBM [16]. 
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The expression of C/EBPβ and STAT3 correlates with 
the mesenchymal phenotype of GBM and predicts 
poor clinical outcome and these two TF have been 
demonstrated to regulate the mesenchymal transformation 
of glioma cells [15, 16]. The downstream mechanisms by 
which these TFs mediate and maintain the mesenchymal 
phenotype of glioma are just beginning to be identified.
Related to testis-specific, vespid and pathogenesis 
protein 1 (RTVP-1) was originally cloned from 
human GBM cell lines by two groups and was termed 
glioma pathogenesis-related protein - GLIPR1 [17] 
or RTVP-1 [18]. RTVP-1 contains a putative signal 
peptide, a transmembrane domain and a SCP domain, 
with a yet unknown function. This domain is also found 
in other RTVP-1 homologs including TPX-1 [19], the 
venom allergen antigen [20] and group 1 of the plant 
pathogenesis-related proteins (PR-1). We recently 
reported that RTVP-1 is not detected in normal brain 
specimens, is highly expressed in astrocytic tumors and 
that the expression of RTVP-1 correlates with the degree 
of malignancy of these tumors. Moreover, overexpression 
of RTVP-1 increases glioma cell proliferation, invasion 
and anchorage-independent growth, whereas its silencing 
induces apoptosis in glioma cells [21]. RTVP-1 expression 
is upregulated by the tumor-promoting protein kinase C 
(PKC) isoforms PKCα and PKCε while PKCd exerts 
an opposite effect [22]. The regulation of RTVP-1 by 
these PKC isoforms was at least partly mediated by 
the TF serum response factor (SRF) which is known 
to be differently regulated by these PKC isoforms. In 
addition, RTVP-1 expression in GBM is regulated by 
hypermethylation [23].
RTVP-1 has been also reported to be highly expressed 
in invasive melanoma cells and to regulate melanoma cell 
invasion [24]. In addition, high expression levels of RTVP-1 
and its association with tumorigenesis have been reported 
in Wilms’ tumors [25]. In contrast, RTVP-1 functions as a 
tumor suppressor in prostate cancer [26].
Here, we studied the function of RTVP-1 in the 
mesenchymal transformation of GBM and found that it 
was highly expressed in the mesenchymal GBM subtype 
compared to other subtypes and its expression was induced 
by and correlated with the expression of STAT3 and 
C/EBPβ. Moreover, we found that RTVP-1 regulated the 
mesenchymal transformation of both glioma cell lines and 
GSCs and that some of its effects were mediated by IL-6.
RESULTS
RTVP-1 is highly expressed in the mesenchymal 
subtype of GBM and predicts poor  
clinical outcome
We previously reported that RTVP-1 is expressed 
in astrocytic tumors in a grade-dependent manner but 
is almost undetectable in normal brain [21]. Moreover, 
RTVP-1 regulated the proliferation and invasion of 
glioma cells [22]. In this study, we further examined 
the role of RTVP-1 in glioma cell migration and in the 
mesenchymal transformation of these cells. We first 
examined whether RTVP-1 expression was associated 
with the mesenchymal subtype of GBM, which is known 
to be associated with increased degree of infiltration 
and predicts poor clinical outcome. Using The Cancer 
Genome Atlas (TCGA data portal) [27], we analyzed 
the relative expression of RTVP-1 in the different 
subtypes of GBM. We found that the mean expression 
of RTVP-1 was significantly higher in the mesenchymal 
subtype (P < 0.0001) compared to the proneural, 
GCIMP, neural and the classical GBM subtypes 
(Fig. 1A), whereas its expression was significantly 
lower in the GCIMP subtype compared with the other 
GBM subtypes (Fig. 1A, Suppl. Table S1). Moreover, 
as presented in Fig. 1B and 1C, RTVP-1 expression in 
GBM was positively correlated with the mesenchymal 
metagene score (Pearson correlation 0.78, P < 0.0001) 
and negatively correlated with the proneural metagene 
score (Pearson correlation -0.583, P < 0.0001); both 
were generated from the recently reported mesenchymal 
and proneural genes lists [10]. These analyses indicate 
that RTVP-1 is preferentially expressed in the 
mesenchymal subtype of GBM and may have a role in 
the proneural-to-mesenchymal transformation of these 
tumors.
Using the TCGA data [27], we also found that 
patients with GBM expressing low levels of RTVP-1 have 
a significantly prolonged disease-free survival compared 
to patients with tumors expressing high levels of this 
protein (1062 days vs. 333 days, P = 0.00014) (Fig. 1D). 
Interestingly, low expression of RTVP-1 in GBM tumors 
is a more significant predictive factor of prolonged 
disease-free survival than the absence of mesenchymal 
gene expression signature (Fig. S1). We also used the 
REMBRANDT (Repository of Molecular Brain Neoplasia 
Data) [28] data portal and found that high expression of 
RTVP-1 was significantly associated with worse clinical 
outcome compared with tumors expressing either 
intermediate or low levels of RTVP-1 (Fig. 1E).
The transcription factors C/EBPβ and STAT3 
bind to and regulate RTVP-1 expression
We next examined whether RTVP-1 is regulated 
by C/EBPβ and STAT3, the two transcription factors 
that were recently reported as master regulators of the 
mesenchymal transformation of glioma [16]. Analyzing 
RTVP-1 promoter for transcriptional regulatory elements 
using the MatInspector software revealed several different 
putative binding sites for C/EBPβ and STAT3 (Fig. S2). 
Using chromatin immunoprecipitation (ChIP) assay, we 
further validated that the RTVP-1 promoter binds both 
C/EBPβ and STAT3 in the U87 glioma cells (Fig. 2A).
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We next examined the effects of C/EBPβ, STAT3 
and C/EBPβ + STAT3 overexpression on the promoter 
activity of RTVP-1. Cloning and characterization of the 
RTVP-1 promoter was recently reported [21]. For these 
experiments we co-overexpressed the above TFs alone 
and in combination with a RTVP-1 promoter fragment 
that was cloned into a luciferase-based vector as described 
previously [22]. Overexpression of C/EBPβ, STAT3 or 
C/EBPβ + STAT3 in A172 glioma cells (that express low 
levels of RTVP-1), increased the promoter activity of 
RTVP-1 as measured by luciferase assay (Fig. 2B) and 
the expression of RTVP-1 (Fig. 2C), whereas, silencing of 
C/EBPβ, STAT3 or C/EBPβ + STAT3 in the primary GSCs 
HF2355 (Fig. 2D) downregulated RTVP-1 expression 
(Fig. 2E). Similar effects were obtained with additional 
shRNA constructs (data not shown).
To further analyze the regulation of 
RTVP-1 expression in glioma cells we employed IL-6 
which phosphorylates and activates STAT3. Treatment of 
A172 glioma cells with IL-6 upregulated the expression 
of RTVP-1 in glioma cells (Fig. 2F) and the activity of the 
RTVP-1 promoter (Fig. 2G). To examine the role of STAT3 
activation in the induction of RTVP-1 by IL-6, we employed 
a STAT3 dominant negative mutant in which tyrosine 705 
was mutated to phenylalanine (STAT3 DN). Overexpression 
of the STAT3 DN in the U87 glioma cells abrogated the 
increased promoter activity (Fig. 2H) and the expression 
of RTVP-1 induced by IL-6 (Fig. 2I). Moreover, using the 
TCGA data set we found that RTVP-1 expression in GBM 
specimens was positively correlated with the expression 
of STAT3 (Fig. S3A), C/EBPβ (Fig. S3B) and C/EBPβ + 
STAT3 expression (Suppl. Fig. S3C) (Pearson correlation: 
0.728, 0.349, 0.673 respectively, P < 0.0001 for all).
RTVP-1 induces and is required for the 
maintenance of the mesenchymal phenotype  
in glioma cells
After demonstrating that RTVP-1 is preferentially 
expressed in the mesenchymal subtype of GBM and 
Figure 1: RTVP-1 is highly expressed in the mesenchymal subtype of GBM and predicts poor clinical outcome. Upregulated 
RTVP-1 expression vs. all other samples, P > 0.0001. RTVP-1 gene expression in the five GBM subtypes of 481 GBM specimens was 
analyzed using the TCGA data portal as described in the methods A. Scatter plot of RTVP-1 expression versus the mesenchymal B. and 
the proneural C. metagene scores in TCGA GBM dataset of 259 patients. Details regarding the calculation of the metagene score and 
its definition are described in the method section. Kaplan-Meier curves comparing patients with GBM expressing high vs. low levels of 
RTVP-1 were determined using TCGA dataset D. The tumor samples were partitioned into two groups of equal size depending on their 
levels of RTVP-1. Shown are the Kaplan-Meier curves for the corresponding samples with entries in the ‘‘Days to Tumor Recurrence’’ 
field. P-values for change in survival are assessed by a log-rank test. P < 0.00014. Kaplan-Meier survival plot for 343 GBM patients with 
differential RTVP-1 gene expression was analyzed using REMBRANDT E.
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Figure 2: The TFs C/EBPβ and STAT3 and IL-6 regulate RTVP-1 expression. Chromatin immunoprecipitation (ChIP) assay 
was performed according to the manufacturer's instruction using anti-STAT3 or anti-C/EBPβ antibodies A. Anti-GST antibody was used 
as a control non-relevant antibody (NRA). The specific region in the RTVP-1 promoter was amplified by PCR using specific primers. 
Total chromatin before immunoprecipitation was used as positive control for the PCR (INPUT) and the OLR1 gene was used as a negative 
control (A) A172 cells were co-transfected with C/EBPβ, STAT3 or C/EBPβ + STAT3 plasmids and with the RTVP-1 promoter cloned into 
luciferase vector for 48 h. Dual-luciferase reporter assays were conducted and the results were normalized to Renilla luciferase activity as 
a control for transfection efficiency and cell number B. C/EBPβ, STAT3, STAT3+C/EBPβ or a control vector were overexpressed in A172 
cells C. or silenced in the HF2355 GSCs D. and the expression of RTVP-1 was measured by Western blot analysis C, E. U87 cells were 
treated with IL-6 (50 or 100 ng/ml) and the expression of RTVP-1 was determined by qRT-PCR F. A172 cells transfected with the RTVP-1 
promoter in luciferase plasmid were treated with IL-6 G. U87 cells were overexpressed with a STAT3 Y705F mutant followed by treatment 
with IL-6 (50 ng/ml, H.). Dual luciferase reporter assays were performed and the results were normalized to Renilla luciferase activity as a 
control for transfection efficiency G, H. The expression of RTVP-1 mRNA in these samples was determined by qRT PCR I. The results are 
representative of three different experiments that gave similar results A, C, D, E, F, I or are the means ± SE of three different experiments 
B, G, H.*P < 0.01.
Oncotarget22684www.impactjournals.com/oncotarget
is positively regulated by C/EBPβ and STAT3, we 
next examined if RTVP-1 plays a role in regulating 
the mesenchymal phenotype of glioma cells. 
Overexpression of RTVP-1 in A172 glioma cells induced 
a mesenchymal-like morphology (Fig. 3A), upregulated 
the mesenchymal markers fibronectin 1 (FN) and 
α-SMA (Fig. 3B) and increased cell migration of these 
cells (Fig. 3C-3D). Silencing of RTVP-1 in the two 
human glioma cell lines, U251 and U87 resulted in 
downregulation of the mesenchymal markers FN, α-SMA 
and CTGF (Fig. 3E-3F) and in the inhibition of U87 
glioma cell migration (Fig. 3G). Moreover, silencing of 
RTVP-1 abrogated the adipogenic and chondrogenic 
differentiation of these cells in response to specific 
induction media (Fig. 3H). Taken together, these results 
demonstrate that RTVP-1 induces and is required for the 
mesenchymal phenotype of glioma cells.
RTVP-1 promotes and maintains the 
mesenchymal phenotype and stemness of GSCs
Since GSCs play a major role in GBM migration, 
therapy resistance and tumor recurrence, we examined 
the role of RTVP-1 also in the mesenchymal 
transformation of these cells. As previously reported 
[29], RTVP-1 was not expressed in human NSCs but 
was expressed to a different degree in various GSC 
cultures (Fig. 4A). Overexpression of RTVP-1 in the 
HF2587 and HF2354 GSCs (that express low levels 
of this protein), inhibited their neural differentiation 
when incubated in a differentiation medium, as 
indicated by their morphology (Fig. 4B), decreased the 
expression of the neural markers GFAP and MAP2 and 
upregulated the expression of the mesenchymal markers 
FN, α-SMA and CTGF (Fig. 4C and 4D) and genes 
Figure 3: RTVP-1 induces and is required for maintaining the mesenchymal phenotype of glioma cells. A172 cells were 
transduced with a lentivirus vector expressing RTVP-1. The cells were analyzed for cell morphology after 72 h A. and the expression of 
the mesenchymal marker proteins FN and α-SMA was determined using Western blot analysis B. Cell migration was analyzed 16 h later by 
scratch assay and images were acquired using OLYMPUS IX50 microscope and 4x objective C. The area of cell migration was analyzed 
using ImageJ software D. *P < 0.001. U251 E. and U87 F. cells were silenced with two different RTVP shRNAs and were analyzed for 
the expression of FN, CTGF and α-SMA using Western blot analysis. U87 cells were silenced with two RTVP-1 shRNAs for 48 h, cell 
migration was determined using a scratch assay and the area of cell migration was analyzed using ImageJ software G. U87 cells were 
silenced with two different RTVP shRNAs and were cultured with induction media for three mesenchymal lineages. 21 days later, cells 
were stained with oil O-red, alcian blue and alizarin red S for evaluation of adipogenic, chondrogenic and osteogenic differentiations, 
respectively H. The results are representative of three different experiments that gave similar results. *P < 0.001 **P < 0.01.
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Figure 4: RTVP-1 induces a proneural to mesenchymal transformation of GSCs and is required for maintaining 
the mesenchymal phenotype of these cells. The expression of RTVP-1 in ten different primary GSCs that were established 
from GBM specimens and in two hNSCs was analyzed using qRT-PCR A. GSCs were transduced with lentivirus vectors expressing 
RTVP-1 or a control vector, plated on poly-L-lysine and cultured under neural differentiation condition for 10 days. The morphological 
differentiation of the cells B. and the expression of different neural and mesenchymal markers were analyzed using Western blot analysis 
C. or by immunofluorescence staining D. GSCs overexpressing RTVP-1 were also analyzed for the expression of different mesenchymal 
markers using qRT-PCR E. GSCs were transduced with lentivirus vectors expressing RTVP-1 or control shRNAs and analyzed for cell 
migration using transwell migration assay F. The expression of various neural and mesenchymal markers was measured in the HF2355 
GSCs cells using qRT- PCR G. The RTVP-1 silenced GSCs were cultured with adipogenic induction medium for 24 days and then stained 
with alizarin for the analysis of their osteogenic differentiation H. The results are representative of three different experiments that gave 
similar results. *P < 0.001. GSCs silenced for RTVP-1 were analyzed for the expression of stemness markers using qRT-PCR. P < 0.01 I. 
GSCs were plated on poly-L-lysine and cultured under neural differentiation condition and the expression of RTVP-1 and neural markers 
were analyzed using Western blot analysis J. The results are representative of three different experiments that gave similar results.
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that are associated with specific mesenchymal lineages 
(Fig. 4E).
To further elucidate the role of RTVP-1 in regulating 
the mesenchymal phenotype of GSCs, we employed 
lentivirus vectors expressing shRNAs targeting RTVP-1. 
Silencing of RTVP-1 in the HF2355 and HF2490 
GSCs markedly decreased cell migration (Fig. 4F), 
downregulated the expression of the mesenchymal 
markers CTGF, FN, α-SMA and YKL-40 and upregulated 
the expression of the neural markers Olig2 and GFAP 
(Fig. 4G). Furthermore, silencing of RTVP-1 decreased 
the osteogenic differentiation of GSCs (Fig. 4H).
During the process of mesenchymal 
transformation, cancer cells acquire stem cell-like 
characteristics including increased self-renewal 
ability, migration and formation of micro 
metastases [30]. Similarly, the self-renewal ability 
is a hallmark of GSC stemness [31, 32]. We recently 
demonstrated that RTVP-1 promoted the self-renewal 
and stemness of GSCs via the activation of the 
CXCR4/Shh/Gli/Nanog pathway [29]. We further 
demonstrated now that silencing of RTVP-1 in GSCs 
decreased the expression of Nanog, Sox2, OCT4 and 
CD44 (Fig. 4I). During differentiation, GSCs lose their 
stemness and differentiate into the different neural 
lineages; a process that is characterized by the loss of 
stemness markers and acquisition of neural markers. We 
found that during GSC differentiation, the expression of 
endogenous RTVP-1 protein was significantly decreased 
along with the acquisition of the neural markers GFAP 
and MAP2 (Fig. 4J). Altogether, these results indicate 
that RTVP-1 has a functional role in the maintenance of 
GSCs and their stemness potential.
RTVP-1 induces mesenchymal differentiation  
of human NSCs
Since glioma cells and GSCs express different 
aberrant pathways and genetic alterations that could 
cooperate with RTVP-1 to induce and maintain 
mesenchymal transformation, we examined whether 
overexpression of RTVP-1 in hNSCs is sufficient to 
trigger mesenchymal phenotypes. Transduction of hNSCs 
with a lentivirus vector expressing RTVP-1 markedly 
inhibited their neural differentiation when plated on 
poly-L-lysine coated plates in the absence of EGF and 
FGF, and maintained these cells as undifferentiated 
neurospheres (Fig. 5A). Furthermore, overexpression of 
RTVP-1 induced downregulation of the neuronal marker 
β3-tubulin and the astrocyte marker GFAP and induced 
the expression of the mesenchymal markers CD44, CTGF, 
FN and α-SMA (Fig. 5B). Moreover, overexpression of 
RTVP-1 resulted in the mesenchymal differentiation of 
these cells to adipocytes and osteoblasts as indicated by the 
increased presence of oil red-O and alizarin red S-positive 
cells (Fig. 5C). RTVP-1 also significantly increased hNSC 
Figure 5: RTVP-1 induces mesenchymal differentiation of hNSCs. hNSCs were transduced with lentivirus vectors expressing 
RTVP-1 or a control vector. The cells were maintained as spheroids or plated on poly-L-lysine and cultured in neural differentiation 
medium for 5 days. Cell morphology was determined using phase contrast microscopy A. The expression of mesenchymal and neural 
markers was determined using qRT-PCR B. The cells were also cultured in induction media for mesenchymal differentiation. Twenty-one 
days later, cells were stained with oil O-red and alizarin red S for the evaluation of adipogenic and osteogenic differentiation, respectively 
C. Cell migration of the RTVP-1 overexpressing cells was determined using transwell migration assay after 8 h of incubation D. The results 
are representative of three different experiments that gave similar results. *P < 0.001.
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cell migration as determined by transwell migration assay 
(Fig. 5D). Collectively, these findings demonstrate that 
overexpression of RTVP-1 in hNSCs inhibited neural 
differentiation and promoted mesenchymal differentiation 
of these cells.
Glioma global gene network changes induced  
by silencing of RTVP-1
To delineate the mechanisms by which RTVP-1 
induces and maintains the mesenchymal transformation of 
glioma cells, we subjected U87 glioma cells silenced for 
RTVP-1 to microarray analyses. We found 3498 genes that 
were significantly downregulated (<3 fold) and 142 genes 
that were significantly upregulated (>3 fold) in U87 cells 
silenced for RTVP-1 compared to cells expressing a control 
shRNA. qRT–PCR analysis confirmed the downregulation 
of several microarray inferred mesenchymal genes in the 
RTVP-1 silenced cells (Fig. 6A). Further analyses of 
functional pathways using DAVID revealed that silencing 
of RTVP-1 induced downregulation of functional groups 
related to mesenchymal phenotype and to cell locomotion 
(Fig. 6B). To further confirm the pivotal role of RTVP-1 in 
regulating the mesenchymal phenotype of glioma cells we 
calculated the average expression levels of all the genes 
in the different subtypes of glioma (according to Verhaak 
proneural, neural, classical and mesenchymal gene lists 
[10]) and found that silencing of RTVP-1 induced a 
significant (P < 0.0001) downregulation in the expression 
of the mesenchymal genes compared to genes associated 
with proneural, neural and classical glioma subtypes 
(Fig. 6C).
We next used gene set enrichment analysis 
(GSEA) to identify gene sets that were enriched in 
the RTVP-1 silenced U87 cells. This analysis further 
confirmed downregulation of mesenchymal gene 
expression (Fig. 6D) and upregulation of proneural 
gene expression (Fig. 6E). In addition, GSEA revealed 
that RTVP-1 silencing in glioma cells induced 
downregulation of several pathways including those 
associated with stemness, such as IL-6, CXCR4 and NKT 
(Suppl. Table S2).
Figure 6: Global gene network changes induced by silencing of RTVP-1 in glioma cells. U87 cells were silenced for RTVP-1 
and after 3 days gene array analysis was performed as described in the methods. The expression of RTVP-1 and additional 8 genes that were 
downregulated in RTVP-1 silenced cells was validated using qRT-PCR A. *P < 0.001. Bar graph showing the top 10 gene ontology 
(GO) terms associated with the three-fold or greater of RTVP-1-silenced genes in U87 cells is presented as ranked by P-values. The axis 
represents the log10 of the P-value as determined by DAVID functional analysis B. The box plot represents the average expression levels 
of all the genes in the different glioma subtypes (i.e., Verhaak metagene scores for proneural, neural, classical and mesenchymal gene lists) 
in U87 glioma cells silenced for RTVP-1 C. GSEA analysis showing downregulation of genes associated with the mesenchymal phenotype 
D. and upregulation of genes associated with the proneural phenotype E. in RTVP-1-silenced U87 cells, with enrichment scores of -1.58 
and 1.18, respectively; P (family-wise error rate) = 0.000; q (false discovery rate, FDR) = 0.000. A list of <3 fold and >3 fold of altered 
genes in RTVP-1 silenced cells was submitted to the STRING database. A functional protein association network was created using the 
parameters custom confidence level 0.24 and showing no more than five integrators. The type of protein–protein association (neighborhood, 
gene fusion, concurrence, experimental data, databases, text mining) corresponds to the connection color F.
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We next analyzed the downregulated (<3 fold) 
and the upregulated (>3 fold) gene using STRING 
(http://string-db.org/) and found four main gene 
networks consisting of IL-6, BCL2, PTGS2/COX-2 
(prostaglandin endoperoxide synthase 2 gene) and 
CXCR4, that were regulated in glioma cells silenced for 
RTVP-1 (Fig. 6F).
RTVP-1 mediates the mesenchymal 
transformation of glioma cells  
via the IL-6 pathway
Based on our GSEA and STRING analyses, we first 
focused on the role of IL-6 in the effects of RTVP-1 on the 
mesenchymal transformation of glioma cells. The IL-6 
pathway is aberrant in GBM, correlated with the degree 
of malignancy and supports cell proliferation, migration, 
tumor growth and GSC tumorigenesis [33–35].
We first examined whether IL-6 can induce 
mesenchymal transformation of glioma cells. For 
this analysis we treated A172 glioma cells and the 
HF2354 GSCs with IL-6 and found that this treatment 
upregulated the expression of the mesenchymal markers 
vimentin and FN in these cells (Fig. 7A), increased cell 
migration of the A172 cells and of the GSCs, HF2354 
and HF2359 (Fig. 7C). Moreover, silencing of IL-6 
downregulated the expression of the mesenchymal 
marker vimentin in the HF2355 and HF2490 GSCs (Fig. 
7D) and inhibited cell migration of U87 glioma cells and 
of the HF2490 and HF2303 GSCs (Fig. 7E).
We next examined whether the mesenchymal 
transformation of glioma induced by RTVP-1 was 
mediated by IL-6. For this experiment we silenced 
the expression of IL-6 in A172 cells and examined the 
effects of RTVP-1 overexpression in the silenced cells. 
Silencing of IL-6 abrogated both cell migration (Fig. 
7F) and the expression of mesenchymal markers, FN 
and vimentin induced by overexpression of RTVP-1 
(Fig. 7G).
Using the TCGA data portal we analyzed the 
relative expression of IL-6 in the different subtypes 
of GBM patients. We found that similar to RTVP-1, 
mean expression levels of IL-6 were significantly 
higher in mesenchymal GBM (P < 0.0001) compared 
to the GCIMP, proneural, neural or classical subtypes 
(Fig. 7H). The expression of IL-6 in the GCIMP GBM 
was significantly lower compared to all other subtypes 
(Table S3). Moreover, the expression of RTVP-1 was 
positively correlated with the expression to IL-6 in GBM 
specimens (Pearson correlation: 0.512, P < 0.0001) and 
the relative expression of both appeared to be higher in the 
mesenchymal subtype (Fig. 7I).
In summary, these data strongly demonstrate that the 
mesenchymal transformation of glioma cells induced by 
RTVP-1 is, at least partly, mediated by the IL-6 pathway.
RTVP-1 silencing in GSCs prolongs the survival 
of mice bearing intracranial xenografts
Our results demonstrate an important role of 
RTVP-1 in the mesenchymal transformation and stemness 
of GSCs. We therefore examined the impact of RTVP-1 
silencing on the tumorigenic capacity of GSCs in vivo. 
For these experiments we employed the GSC HF2303 that 
exhibits strong and stable mesenchymal characteristics. 
Since complete silencing of RTVP-1 in GSCs arrested 
cell growth and neurosphere formation (data not shown), 
we employed GSCs in which RTVP-1 was silenced by 
about 60% (Fig. 8A). These cells exhibited decreased 
neurosphere formation as described previously for 
other GSCs (Fig. 8B, 8C). Intracranial implantation of 
these cells into immunocompromised mice significantly 
increased the mean survival of tumor-bearing mice 
compared to the control group (107.8 days vs. 73.3 days, 
P = 0.00005) (Fig. 8D). These data demonstrate that 
RTVP-1 plays a major role in promoting the tumorigenic 
capacity of GSCs in vivo similar to its role in tumor 
aggressiveness in GBM patients (Fig. 1D).
DISCUSSION
Despite recent advances in therapeutic approaches 
for the treatment of GBM, the survival of patients 
diagnosed with these tumors remains dismal. This is 
mainly attributed to the high level of infiltration and 
treatment resistance of residual GSCs, which eventually 
lead to tumor recurrence. GBM have been classified into 
several subtypes based on gene expression profile, with the 
two subtypes, proneural and mesenchymal, being the most 
robust and generally consistent among the classification 
schemes [9, 10, 15, 36].
Recent studies have shown that during glioma 
progression and recurrence, tumor cells acquire 
mesenchymal and lose proneural gene expression 
signature. The mesenchymal transformation of GBM 
is associated with tumor aggressiveness, therapy 
resistance and poor clinical outcome [9, 13, 14]. Thus, 
deciphering the mechanisms underlying the mesenchymal 
transformation of GBM is essential for identifying 
therapeutic targets and improving patient survival.
We previously reported that GLIPR1/RTVP-1 
acts as tumor promoter in GBM and that its expression 
is increased in astrocytic tumors, in a grade-dependent 
manner [21]. Moreover, RTVP-1 plays a major role in 
promoting glioma cell migration and invasion. In this 
study we further characterized RTVP-1 expression and 
function in GBM, glioma cells and GSCs focusing on its 
role in the mesenchymal transformation of these cells.
Using gene expression data from the REMBRANDT 
[28] and TCGA data portals [27], we found that high 
expression of RTVP-1 in GBM specimens predicted poor 
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Figure 7: RTVP-1 mediates the mesenchymal transformation of glioma cells via the IL-6 pathway. A172 glioma cells and 
the HF2354 GSCs were treated with 50 ng/ml of IL-6 for 48 h. The expression of vimentin and fibronectin was analyzed using Western 
blot analysis A. A172 cells B. and the HF2354 and HF2359 GSCs C. were analyzed for cell migration using transwell migration assay. U87 
and GSCs were silenced for IL-6 or transfected with a control siRNA duplex. The expression of vimentin was analyzed using Western blot 
analysis D. and cell migration was analyzed using transwell migration assay E. The migration of A172 cells and GSCs silenced for IL-6 and 
overexpressing RTVP-1 was analyzed using transwell migration assay F. Mesenchymal marker expression was analyzed for the HF2587 
GSCs as determined by RT-PCR G. IL-6 gene expression in the different subtypes of GBM was analyzed in TCGA dataset of 418 GBM 
patients H. Scatter plot of RTVP-1 expression versus IL-6 expression was generated using the TCGA dataset I. Each point is colored by the 
respective Verhaak classification with mesenchymal (red), classical (blue), neural (green) and proneural (purple). Tumors with unknown 
classification are grey. The results are representative of three different experiments that gave similar results. *P < 0.001.
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prognosis. In addition, the expression of RTVP-1 was 
significantly higher in the mesenchymal GBM as compared 
to the other GBM subtypes. We next found that the mean 
expression of all genes associated with the mesenchymal 
signature was highly correlated with the expression of 
RTVP-1 in 259 GBM specimens, whereas the expression 
of genes that are associated with the proneural signature 
was inversely correlated with RTVP-1 expression. These 
data suggest that RTVP-1 may have a role in mediating the 
mesenchymal transformation of GBM.
Epithelial-to-mesenchymal transition (EMT) is 
essential for the development of malignant carcinoma 
metastasis and drug resistance [37–39]. Recently, 
mesenchymal transformation has also been shown to 
occur in GBM [40–43] and has been reported to be 
regulated by STAT3 and C/EBPβ [16]. We found the 
RTVP-1 promoter binds both STAT3 and C/EBPβ and 
that these TFs regulated the RTVP-1 promoter activity 
and RTVP-1 expression. Moreover, treatment of glioma 
cells with IL-6 upregulated RTVP-1 expression and 
activation of the RTVP-1 promoter in glioma cells via 
activation of STAT3. Using TCGA data analysis, we found 
a positive correlation between the expressions of STAT3, 
C/EBPβand RTVP-1 in GBM specimens, supporting a 
role of these TFs in the regulation of RTVP-1 expression. 
While the function of C/EBPβ in glioma progression is 
Figure 8: Silencing of RTVP-1 in GSCs prolongs the survival of mice bearing GSC-derived intracranial 
xenografts. HF2303 GSCs were silenced for RTVP-1 using lentivirus vectors expressing specific shRNAs. RTVP-1 expression was 
determined using Western blot analysis A. Cell morphology is demonstrated using phase contrast microscopy B. and neurosphere formation 
analysis was determined after 14 days C. *P < 0.001. Kaplan-Meier survival curves of mice bearing intracranial xenografts derived from 
the HF2303 GSCs silenced for RTVP-1 or control shRNAs (N = 12) was determined D. P < 0.001.
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less defined, STAT3 has a well-characterized role in cancer 
progression and its activation in GBM is associated with 
the aggressive mesenchymal subtype and poor overall 
survival [33, 44, 45]. Targeting C/EBPβ and STAT3 in 
GBM patients may be challenging since these TFs regulate 
important functions in the normal brain. STAT3 was 
found to induce astrocytic differentiation and to inhibit 
neuronal differentiation of neural stem/progenitor cells, 
and C/EBPβ was found to promote neurogenesis and 
inhibits oligogenesis [46–49]. Therefore, the identification 
of tumor-specific pathways downstream of these TFs may 
have important mechanistic and therapeutic implications.
Our findings that RTVP-1 was preferentially 
expressed in the mesenchymal subtype of GBM 
and predicted poor clinical outcome and the fact the 
promoter of RTVP-1 contains binding sites for STAT3 
and C/EBPβ led us to examine the involvement of this 
protein in the regulation of the mesenchymal phenotype 
of GBM. We found that overexpression of RTVP-1 
induced a mesenchymal phenotype and differentiation in 
glioma cells, whereas silencing of RTVP-1 inhibited the 
mesenchymal signature of these cells, suggesting a role 
of RTVP-1 in the mesenchymal transformation process.
GBM contain a small subpopulation of 
self-renewing and highly tumorigenic cancer stem cells 
(GSCs) which contribute to therapy resistance and tumor 
recurrence and have been shown to be critical therapeutic 
targets [50–52]. More recently, it has been shown that 
GSCs can undergo a mesenchymal transformation 
in a TNF-α/NF-kB-dependent manner which confers 
resistance to radiotherapy [13]. We found that RTVP-1 
is preferentially expressed in GSCs compared to normal 
hNSCs. Overexpression of RTVP-1 inhibited the neural 
differentiation and induced a significant mesenchymal 
transformation of GSCs, whereas, silencing of endogenous 
RTVP-1 in GSCs induced the opposite effects. 
Altogether, our results indicate that RTVP-1 mediated 
the mesenchymal transformation of GSCs and silencing 
of RTVP-1 inhibited the proneural-to-mesenchymal 
transit of these cells. Importantly, overexpression of 
RTVP-1 in normal hNSCs resulted in inhibition of the 
neural differentiation capacity and induced an acquisition 
of mesenchymal characteristics, indicating that RTVP-1 
reprograms human NSCs along the mesenchymal lineage.
One of the main factors contributing to therapy 
failure in GBM is the activation of specific signaling 
pathways in GSCs which are associated with resistance to 
both chemo- and radiotherapy [13, 53, 54]. It was recently 
suggested that during therapy, GSCs can stay dormant and 
their high self-renewal capacity can cause local recurrence 
or an infiltrative lesion at a later time. It has also been 
suggested that stemness of tumor cells may be closely 
associated with mesenchymal transformation of these 
cells [30, 55–57]. Indeed, we recently demonstrated that 
RTVP-1 regulates the stemness of GSCs as determined 
by increased self-renewal and expression of the stemness 
genes Oct4 and Nanog and decreased differentiation 
ability downstream of miR-137 and upstream of the 
CXCR4-Shh-Gli pathway [29].
To examine the mechanism by which RTVP-1 
promoted and maintained the mesenchymal transformation 
of glioma, we performed microarray analysis of gene 
expression of glioma cells silenced for RTVP-1. By 
combining analysis of microarray data and the average 
expression levels of all the genes of the different GBM 
subtypes in TCGA, we further confirmed that silencing 
of RTVP-1 inhibited the mesenchymal and induced the 
proneural phenotypes of glioma cells. Using GSEA we 
found that silencing of RTVP-1 induced downregulation 
of genes that are targets of the TFs STAT3 and C/EBPβ, 
which further supports our data that RTVP-1 is a 
downstream mediator of STAT3 and C/EBPβ effects on 
the mesenchymal transformation of glioma cells. Further 
analysis using STRING identified four main gene 
networks (IL-6, BCL2, PTGS2 and CXCR4) that were 
downregulated in glioma cells silenced for RTVP-1. The 
identification of CXCR4 as a major signaling molecule 
in these cells further confirmed our recent findings that 
miR-137 inhibited GSC self-renewal and promoted their 
differentiation by targeting RTVP-1 which downregulated 
CXCR4 [29].
IL-6 is a physiological activator of C/EBPβ and 
STAT3 that was found by us to upregulate RTVP-1 
expression in a STAT3-dependent manner. We therefore 
focused on the role of the IL-6 pathway in RTVP-1 effects 
in glioma cells. The IL-6 pathway is known to be aberrant 
in GBM and to promote cell proliferation, migration 
and tumor growth in vivo [33, 58]. In addition, aberrant 
activation of STAT3 was associated with the tumorigenic 
effects of IL-6 in GSCs [34]. We found that similarly to 
RTVP-1, the expression of IL-6 correlated with the degree 
of malignancy of gliomas and that high IL-6 expression in 
GBM predicted poor prognosis [35].
Recently, IL-6 was shown to promote head 
and neck tumor metastasis by inducing EMT via the 
JAK-STAT3-SNAIL signaling pathway [59]. We 
found that silencing of IL-6 reduced the mesenchymal 
phenotype of glioma cells and GSCs, whereas treatment 
of the cells with IL-6 induced an opposite effect. More 
interestingly, silencing of IL-6 abrogated the effects of 
RTVP-1 on glioma cell migration and on the expression 
of the mesenchymal markers fibronectin and α-SMA. The 
existence of this IL-6-RTVP-1 interaction and its role in 
the mesenchymal transformation of GBM was further 
supported by TCGA data analysis which demonstrated that 
similar to RTVP-1, IL-6 was also preferentially expressed 
in the mesenchymal GBM subtype. More interestingly, we 
found that the expression of RTVP-1 was highly correlated 
with that of IL-6 in GBM specimens particularly in 
the mesenchymal subtype. In summary, these results 
strongly suggest that RTVP-1 mediates the mesenchymal 
transformation of glioma cells, at least partly, via the IL-6 
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pathway and points to the existence of positive regulatory 
pathways linking RTVP-1 and IL-6 via the activation of 
the STAT3 pathway.
GBM patients exhibit poor prognosis due to therapy 
resistance and invasiveness of residual tumor cells and 
tumor recurrence after resection, characteristics that are 
attributed to GSCs. Recently, it was reported that neural 
differentiation of GSCs decreased their tumorigenic 
potential and rendered them more susceptible to different 
therapies [60]. Thus, silencing of RTVP-1 in GSCs which 
decreases their self-renewal and promotes the neural 
differentiation of these cells, can be employed as a novel 
therapeutic approach to abolish the oncogenic potential 
of GSCs with no damage to normal cells in the tumor 
microenvironment [50].
We further examined the role of RTVP-1 in 
the tumorigenic potential of GSCs. Since complete 
knockdown of RTVP-1 in GSCs significantly inhibited 
their cell growth and neurosphere formation, we 
employed stable clones of GSCs that were only partially 
silenced for RTVP-1 expression. We found that partial 
knockdown of RTVP-1 expression in primary GSCs 
significantly increased the mean survival of GSC-derived 
xenograft-bearing mice. This finding suggests that 
in addition to the role of RTVP-1 in maintaining the 
mesenchymal phenotype and the stemness potential of 
GSCs, it also maintained the tumorigenic potential of 
GSCs in vivo. Analyzing data of GBM patients from 
the TCGA, a recently published study showed that long 
delay in tumor recurrence is associated with absence 
of the mesenchymal gene expression signature [14], 
raising the possibility that inhibiting this transformation 
may improve GBM patient prognosis. TCGA analysis 
demonstrated that patients with GBM expressing 
low levels of RTVP-1 have significantly prolonged 
disease-free survival (equal to prolonged time to tumor 
recurrence) compared to GBM patients expressing 
high levels of this gene. Moreover, lower expression 
of RTVP-1 in GBM appears to be a more significant 
predictive factor of prolonged disease-free survival than 
the absence of mesenchymal signature.
In summary, our results implicate RTVP-1 as an 
important prognostic marker and major effector in the 
mesenchymal transformation of GBM, glioma cells and 
GSCs downstream of STAT3 and C/EBPβ. This study also 
demonstrates an important positive feedback regulation 
of the IL-6-RTVP-1 pathway that promotes glioma 
cell migration, GSC stemness and the mesenchymal 
transformation of GBM.
MATERIALS AND METHODS
Cell cultures
The glioma cell lines A172, U251 and U87 were 
obtained from the American Type Culture Collection 
(Manassas, VA). Cells were maintained as previously 
described [29].
Generation of primary GSC cultures
All human materials were used in accordance with 
the policies of the Institutional Review Board at Henry 
Ford Hospital. Generation of GSCs from fresh GBM 
specimens was performed as previously described [61]. 
The GSCs were examined for the expression of CD44, 
Bmi-1, CD133, Sox2 and nestin, self-renewal, expression 
of astrocytic, oligodendrocytic and neuronal markers upon 
differentiation and for their tumorigenic potential in nude 
mice [29, 40, 62–64].
Neural and mesenchymal differentiation
For induction of neuronal differentiation, 
GSC neurospheres were seeded on poly-L-lysine 
(Sigma-Aldrich)-coated slide glasses and cultured for 
10 days with DMEM containing 10% FCS as previously 
described [29]. Mesenchymal differentiation was assessed 
in glioma cell lines, GSCs and hNSCs. Adipogenic, 
osteogenic and chondrogenic differentiation was examined 
by incubating the cells with a StemPro® Differentiation 
Kit (Invitrogen Life Technologies, USA) for 3 weeks. 
Adipogenic differentiation was analyzed by staining 
with oil red-O solution (Sigma-Aldrich), osteogenic 
differentiation and mineralization, by staining with 
alizarin red (Sigma-Aldrich) and alcian blue staining 
(Sigma-Aldrich) was used to assess chondrogenic 
differentiation.
Immunofluorescence staining
For immunofluorescence staining, cells were fixed 
with 4% paraformaldehyde for 20 min and permeabilized 
with wash solution (0.1% Triton X-100 and 1% bovine 
serum albumin in PBS) for 20 min. Subsequently, cells 
were incubated with the specific first antibody for 1 h, 
washed three times with wash solution, and incubated 
with the subsequent secondary antibodies and with DAPI 
(Molecular Probes) for nuclear staining. Stained cells were 
observed using an eight-bit, 512 × 512 pixel, confocal 
Zeiss LSM510 microscope and AIM software.
Transduction and transfection of GSCs, NSCs 
and glioma cell lines
Lentivirus vectors (System Biosciences, Mountain 
View, CA) expressing RTVP-1 or control, RTVP-1, 
STAT3 and C/EBPβ shRNAs were packaged and used 
to transduce the cells according to the manufacturer’s 
protocol and as previously described [29]. In addition, 
GSCs, NSCs and glioma cell lines were transduced with 
adenovirus vectors expressing RTVP-1 or control vector at 
5 multiplicity of infection (MOI) for 2 h. The medium was 
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then replaced with fresh medium and the cells were used 
48-h post infection. For each experiments, we employed 
two different shRNA constructs that gave similar results.
Cells were transfected either with the pcDNA3.1 
control vector or with RTVP-1, C/EBPβ, STAT3 
or IL-6 vectors (all plasmids were obtained from 
Addgene (Cambridge, MA) by electroporation using 
the Nucleofector device, protocol number A29 [Amaxa 
Biosystems, Gaithersburg, MD]).
Small interfering RNA transfection
Small interfering RNA (siRNA) duplexes were 
synthesized and purified by Dharmacon (Lafayette, CO). 
The siRNA sequence for targeting RTVP-1 mRNA was 
5′-AAGACTGCGTTCGAATCCATA-3′ (siRNA1). In 
addition, for some of the experiments we used pools of four 
siRNA duplexes for RTVP-1 and IL-6 and for the TF STAT3 
and C/EBPβ that were also obtained from Dharmacon. 
Transfection of siRNAs was done using Oligofectamine 
(Invitrogen) according to the manufacturer’s instructions. 
Experiments were performed 72 h after transfection.
Western blot analysis
Cell pellet preparation and Western blot analysis 
were performed as previously described [22, 29].
Scratch wound healing assay
Cells were plated in a 6-well plate and 48 h later at 
a confluence of 100% a migration gap of approximately 
1 mm was created. The cells were washed with PBS and 
fresh media were added to remove any loose cells. Images 
of the initial scratch and at 16-h post-scratch were acquired 
using OLYMPUS IX50 microscope and 4x objective. To 
analyze cell migration into the scratched area, an average 
of 10 images was evaluated using the ImageJ software.
Transwell migration assay
Transwell chambers (BD Biosciences, San Jose, 
CA) were used for analyzing cell migration as recently 
described [22].
Luciferase reporter assay
Glioma cells were co-transfected with 3 μg 
of the firefly reporter construct and the desired 
expression plasmids or the Renilla control construct by 
electroporation using the Nucleofector device (Amaxa 
Biosystems, Germany). Firefly luciferase activities of 
the transfected cells were determined 24 h after the 
transfection using the dual luciferase assay system 
(Promega, Madison, WI) according to the manufacturer’s 
instructions and as previously described [22].
Chromatin immunoprecipitation assay (ChIP)
Chromatin immunoprecipitation assay (ChIP) 
was performed using a chromatin immunoprecipitation 
assay kit (Upstate, MA) following the manufacturer’s 
instructions and as previously described [22]. Prior to the 
IP procedure, 10% of the supernatant was saved as total 
input chromatin and was processed with the eluted IPs 
beginning with the cross-linking reversal step. After the 
final ethanol precipitation, each IP or input sample was 
resuspended in 50 μl of PCR grade water.
Real-time PCR
Total RNA was extracted using RNeasy midi kit 
according to the manufacturer’s instructions (Qiagen). 
Reverse transcription reaction was carried out using 2 μg 
total RNA as described for the RT-PCR analysis. A primer 
optimization step was tested for each set of primers to 
determine the optimal primer concentrations. Primers, 
25 μL of 2x SYBR Green Master Mix (Invitrogen), 
and 30 to 100 ng cDNA samples were resuspended in a 
total volume of 50 μL PCR amplification solution. The 
following primers were used:
BMP-2-forward 
GCGGAATTCGACTGCGGTCTCCTAAAGGTC,
reverse 
GCGGCGGCCGCTTGCTGTACTAGCGACACCCAC;
osteocalcin-forward ACACTCCTCGCCCTATTG,
reverse GATGTGGTCAGCCAACTC;
RUNX-2-forward CCAGAATGATGGTGTTGACG,
reverse GGTTGCAAGATCATGACTAGGG;
SOX9- forward CGAAATCAACGAGAAACTGGAC,
reverse ATTTAGCACACTGATCACACG;
BMP- 6-forward CAACAGAGTCGTAATCA, 
reverse TTAGTGGCATCCACAAGCTCT;
FN- forward TGGCCAGTCCTACAACCAGT,
reverse CGGGAATCTTCTCTGTCAGC;
α-SMA-forward CCGACCGAATGCAGAAGGA,
reverse ACAGAGTATTTGCGCTCCGAA;
YKL-40 forward TGCCCTTGACCGCTCCTCTGTACC,
reverse GAGCGTCACATCATTCCACTC;
olig2-forward CAAATCTAATTCACATTCGGAAGGTTG,
reverse GACGATGGGCGACTAGACACC
CTGF-forward GGGAAATGCTGCGAGGAGT,
reverse AGGTCTTGGAACAGGCGCTC;
RTVP-1-forward TGCCAGTTTTCACATAATACAC,
reverse GGATTTCGTCATACCAGTTT;
CXCR4 - forward GTCATCTACACAGTCAACCTCTAC,
reverse ACCACCTTTTCAGCCAACAG;
Oct4 - forward ATCAGCCACATCGCCCAGCA,
reverse CCCAGCAGCCTCAAAATCCT;
Sox2-forward TGGGTTCGGTGGTCAAGTC,
reverse CGCTCTGGTAGTGCTGGGA;
S12-forward, TGCTGGAGGTGTAATGGACG,
reverse CAAGCACACAAAGATGGGCT.
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Reactions were run on an ABI Prism 7000 Sequence 
Detection System (Applied Biosystems, Foster City, CA). 
Cycle threshold (Ct) values were obtained from the ABI 
7000 software. S12 or ß-actin levels were also determined 
for each RNA sample as controls.
TCGA data analysis
Level 2 processed gene expression data from the 
public-access clinical data tables were downloaded from 
the TCGA for 517 GBM. The per-sample files were 
merged on the Agilent probe ID to form a single data 
table (SAS v9.2). Expression values were assessed for 
each gene of interest (RTVP-1, C/EBPβ, STAT3, IL-6) 
and averaged across consistent probes. Expression was 
averaged within gene for persons who had more than one 
tumor sample/aliquot analyzed. Progression-free survival 
time is defined as the minimum time to progression or 
death with censoring at last follow-up time if neither 
had occurred at that time. For consistency, the origin of 
tissue was the brain, no prior tumor was recorded and 
the histopathology was noted to be untreated primary 
(de novo) GBM.
REMBRANDT data analysis
All glioma patient data were publicly available in 
de-identified form and obtained from the NCI Repository 
for Molecular Brain Neoplasia Data (REMBRANDT) 
database (https://caintegrator.nci.nih.gov/rembrandt/), 
using the data available on April 22, 2013. There were 
343 glioma patient samples that were correlated between 
RTVP-1 expression and overall survival. Although all of 
the patient samples are represented in the Kaplan–Meier 
Survival Plot, not all of the patients in the database were 
identified for glioma subtype. Thus, only those patients 
that were positively identified as astrocytoma or GBM 
were used in the analysis for calculating the percentage of 
patients with upregulated, intermediate or downregulated 
RTVP-1 expression. The differences between groups were 
analyzed by log-rank P value.
Metagene calculations
The metagenes were determined from the 840 gene 
list of Verhaak [10]. The gene symbols were distributed 
between the 4 classes: Classical N = 162, Mesenchymal 
N = 216, Neural N = 129, and Proneural N = 178. Level 3 
data files for the Agilent gene expression microarrays were 
acquired for all available GBM samples in the TCGA (July 
2012, n = 593). For each tumor, the averaged expression 
of genes in each of the 4 class signatures was calculated 
generating 4 ‘metagene’ scores, one for each subtype for 
every tumor [65].
Microarray analyses
RNA of U87 glioma cells transfected with a control 
of RTVP-1siRNA sequence was used in the hybridizations 
of Unrestricted AMADID Release GE 4x44K expression 
array chip according to the manufacturer’s specifications 
(Agilent). Intensity data were obtained from array images 
and analyzed using R Suite.
Bioinformatics analysis of the microarray results
Target genes that were identified to be associated 
with silencing of RTVP-1 in U-87 MG glioma cells 
were processed using the DAVID Web tool (http://david 
.abcc.ncifcrf.gov) to obtain association of these genes 
with specific GO functional categories. The resulting 
GO terms were ranked from smallest to largest P-values 
after removing GO terms that had 10 or fewer genes 
overlapping with the query gene list. For STRING 
analysis, the list of the gene targets was annotated and 
networks were generated using the STRING (Search 
Tool for the Retrieval of Interacting Genes) analysis 
tool. Each interaction in the database is annotated with 
a benchmarked numerical confidence score, which can 
be used to filter the interaction network at any desired 
stringency. GSEA was performed using the publicly 
available desktop application from the Broad Institute 
(http://www.broad.mit.edu/gsea/software/software_index 
.html). Genes represented by more than one probe were 
collapsed using the XCollapseProbes utility to the probe 
with the maximum value. The gene set database used was 
that of functional sets, s2.symbols.gmt. P values were 
calculated by permuting the genes 1000 times.
GSC-derived xenografts
Following the guidelines of Henry Ford Hospital’s 
IACUC, dissociated GBM neurospheres were inoculated 
intracranially in nude mice (Nu/Nu). Animals were 
anesthetized and a Hamilton syringe was used to inject 
the HF2303 GSCs transduced with lentivirus vector 
expressing RTVP-1 or control shRNAs through a 3-mm 
hole to the right of the bregma, at a depth of 2.5 mm, at 
a rate of 0.5 μL/30 s. The surgical zone was flushed with 
sterile saline, the hole sealed with bone wax, and the skin 
over the injection site sutured. Animals were monitored 
daily and sacrificed at the end of the experiment.
Statistical analysis
The results are presented as the mean values 
± SD. The data of patient specimens are presented 
graphically with median and interquartile range noted. 
Data were analyzed using ANOVA or a Student’s t-test 
with correction for data sets with unequal variances. 
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An age-adjusted t-test was taken from a linear model 
including age as a covariate. Correlation was assessed 
using Pearson’s correlation coefficient and tested against 
a correlation of zero (no correlation). The squared Pearson 
coefficient, or coefficient of determination (R2) for a 
single predictor regression, is given on the scatter plots. 
Kaplan-Meier analysis was used to produce survival curves 
with differences tested between groups by the log-rank 
test. Data were analyzed on a log 2 scale as appropriate.
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